Mazdutide - Wikipedia
Mazdutide (also known as IBI362 or LY3305677) is a dual agonist of the GLP-1 receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM). [ 1 ] [ 2 ] [ 3 ] The drug is developed by Eli Lilly and is currently in multiple Phase III studies [ 4 ] .
Mazdutide (IBI-362) | GLP-1R/GCGR激动剂 | MCE - MCE-生物活性 ...
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K i. : 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM).
PubChem
PubChem is the world's largest collection of freely accessible chemical information. Search chemicals by name, molecular formula, structure, and other identifiers. Find chemical and physical properties, biological activities, safety and toxicity information, patents, …
Mazdutide (IBI-362) | GLP-1R/GCGR Agonist - MedChemExpress
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR).
333-OR: Oxyntomodulin Analog LY3305677 (LY) Improves …
2022年6月1日 · LY is an acylated peptide analog of oxyntomodulin, a dual glucagon and GLP-1 receptor agonist. We conducted 2 randomized, double-blind, phase 1 multiple ascending subcutaneous dosing studies in healthy subjects (S1, NCT03325387) and in T2D patients (S2, NCT03928379) to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics.
Mazdutide|Cas# 2259884-03-0 - GlpBio
Sample solution is provided at 25 µL, 10mM. Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a glucagon-like peptide-1 (GLP-1R)/GCGR co-agonist. Mazdutide has safety and tolerability, and it can be used for research in obesity and type 2 diabetes (T2D)[1][2]. [1]. Chen T, et al.
- 评论数: 30
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor …
2021年9月1日 · IBI362 (LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes. The aim of this randomised, placebo-controlled, multiple ascending dose phase 1b study was to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI362 in Chinese ...
Mazdutide - Eli Lilly and Company - AdisInsight - Springer
2024年9月17日 · Mazdutide (formerly LY 3305677) is a large molecule, long acting analogue of the peptide hormone oxyntomodulin (OXM) and a dual glucagon-like peptide-1 (GLP-1)
An update on peptide-based therapies for type 2 diabetes and …
2023年3月1日 · Among these, the long-acting GLP-1R/GCGR dual agonists NN1177 [15] and LY3305677 (mazdutide), an acylated analogue of oxyntomodulin [26], as well as the GIPR/GCGR/GLP-1R receptor triagonist retatrutide (LY3437943) [27] have entered clinical trials.
(PDF) IBI362 (LY3305677), a weekly-dose GLP-1 and
2021年9月1日 · Mazdutide (also known as IBI362 or LY3305677), a mammalian oxyntomodulin analogue with a fatty acid side chain attached, is being developed as a once-weekly GLP-1 and glucagon receptor dual ...